Endocrine, metabolic & immune disorders drug targets最新文献

{"title":"Nursing Coaching Can Improve the Quality of Life and Immune-Endocrine Condition in Hospitalized Cancer Patients.","authors":"Elsa Vitale, Mohadeseh Motamed-Jahromi, Mohammad Parvaresh-Masoud, Fulvia Lagattolla, Claudia Cormio, Francesca Romito, Raffaella Massafra","doi":"10.2174/0118715303300210240604050438","DOIUrl":"https://doi.org/10.2174/0118715303300210240604050438","url":null,"abstract":"<p><strong>Introduction: </strong>Any cancer diagnosis induces fear and shocking emotional experiences accompanied by anxiety, depression, unpredictability, and distress. The emotional effect of a cancer diagnosis and the rigidity of cancer treatment negatively impact the quality of life (QoL) of patients, and this may continue after treatment. Additionally, emotional distress induces neuroendocrine stress activation systems and raises stress hormone secretion by causing immunological dysfunctions. The present narrative review aims to describe nursing coaching approaches that improve QoL perceptions among cancer patients during their hospitalization.</p><p><strong>Methods: </strong>This review was carried out using the PRISMA methodology until the end of November 2023 through PubMed, Scopus, Web of Science, and CINAHL databases. Researchers systematically collected all the currently available literature. The search terms and boolean operators used to combine keywords were: \"QoL\" AND \"hospitalization\" AND \"cancer patients\" AND \"nursing coaching\".</p><p><strong>Results: </strong>Four manuscripts were selected in the present review. One manuscript belonged to the British Nursing Database and was a mixed-block-randomized study; one belonged to Scopus, which was also in the PubMed, WoS, and Medline and was a study protocol for an RCT and two manuscripts belonged to the PubMed database and were all RCTs.</p><p><strong>Conclusion: </strong>Nursing coaching improved QoL perceptions in cancer patients during their hospitalization. Patients were found to prefer in-person interventions to nurse-led ones, which improved QoL perceptions. However, further interventional studies need to be performed in order to better address coaching nursing interventions during the hospitalization of cancer patients.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Role of Tomography in Addison's Disease due to Adrenal Tuberculosis: A Case Report.","authors":"Juan Eduardo Quiroz-Aldave, María Del Carmen Durand-Vásquez, Elman Rolando Gamarra-Osorio, Sara Elizabeth Zavaleta-Aldave, Alejandra Noemí Zavaleta-Aldave, Jorge Rodríguez-Reyna, Cyntia Mileini Quesquén-García, Luis Alberto Concepción-Urteaga, Samuel Pecho-Silva, Luis Alejandro Rodríguez-Hidalgo, José Paz-Ibarra, Marcio José Concepción-Zavaleta","doi":"10.2174/0118715303305534240709115115","DOIUrl":"https://doi.org/10.2174/0118715303305534240709115115","url":null,"abstract":"<p><strong>Introduction: </strong>Adrenal tuberculosis remains the main cause of primary adrenal insufficiency (PAI) in tuberculosis (TB)-prevalent regions. This case report details the presentation of PAI due to adrenal TB, where the etiological diagnosis involves Abdominal Computed Tomography (CT).</p><p><strong>Case report: </strong>A 37-year-old Peruvian woman with a history of TB contact displayed symptoms of adrenal insufficiency. PAI diagnosis was established, and CT imaging unveiled bilateral adrenal enlargement with calcifications. Treatment with prednisone and anti-TB therapy led to symptomatic improvement. Unfortunately, she succumbed to pneumonia after ten months of follow-up.</p><p><strong>Discussion: </strong>Adrenal TB must be considered in endemic regions and in the presence of a TB history. CT serves as a valuable diagnostic tool, particularly in settings with limited resources, revealing adrenal enlargement and calcifications.</p><p><strong>Conclusion: </strong>In patients with PAI, epidemiological history of TB, and when a rapid biopsy is not feasible, CT proves to be a valuable diagnostic method.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioengineered Cell Therapies for Endocrine Dysfunction: Advancements and Clinical Prospects.","authors":"Dilpreet Singh","doi":"10.2174/0118715303311209240709115156","DOIUrl":"https://doi.org/10.2174/0118715303311209240709115156","url":null,"abstract":"","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aggressive Prolactinoma with Progression to Pituitary Carcinoma: A Case Report.","authors":"Falaguasta Daniele, Garelli Silvia, Mazzucato Marta, Presotto Fabio, Tresso Silvia, De Riva Carlo","doi":"10.2174/0118715303320875240625070226","DOIUrl":"https://doi.org/10.2174/0118715303320875240625070226","url":null,"abstract":"<p><p>Adenomas of the pituitary gland, predominantly prolactinomas, can exhibit aggressive behavior. Aggressive prolactinomas are characterized by radiographic invasion, rapid growth, clinically significant progression despite standard therapies, and recurrence after surgery or radiotherapy. Pituitary carcinoma is rare (0.1-0.2% of pituitary tumors) [1, 2]. Case Presentation: In 2005, a 50-year-old man presented with bitemporal hemianopsia and severe asthenia due to a large pituitary tumor. Hormonal tests revealed hyperprolactinemia and panhypopituitarism; he received hormonal replacement and dopamine agonists (DA) therapy with a reduction in prolactin levels. Ten years later, he experienced tumor regrowth consistent with pituitary apoplexy and VI cranial nerve palsy. MRI showed a macroadenoma with suprasellar extension and compression of the optic structures. The patient underwent transsphenoidal surgery in view of the partially resistant disease. Histopathology showed a pituitary macroadenoma, and immunohistochemistry showed a high mitotic index (Ki-67 80%). In 2016, the patient developed a partial deficit of the left sixth cranial nerve. He underwent a new surgery but with incomplete resection. In view of the aggressive and resistant nature of the disease, he received radiotherapy. In 2020, prolactin levels began to increase again. MRI showed an occipital- temporal lesion. Subsequently, he underwent radiotherapy and started chemotherapy with temozolomide, resulting in the normalization of prolactin levels in the absence of DA therapy. The patient is currently in remission, with no evidence of tumor recurrence. Conclusion: It was found that 15% of prolactinomas are resistant to DAs, and resistance to DA may signal malignant transformation. Therefore, multimodality therapy and molecular analysis are critical for aggressive prolactinomas and pituitary carcinoma.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparisons of Various Anthropometric Indices for Incident Hypertension in Military Young Adults: The CHIEF Cohort Study.","authors":"Kun-Zhe Tsai, Yen-Chen Lin, Chen-Ming Huang, Kai-Ti Yang, Han-Hsing Chen, Hui-Shang Wang, Gen-Min Lin","doi":"10.2174/0118715303303679240611120022","DOIUrl":"https://doi.org/10.2174/0118715303303679240611120022","url":null,"abstract":"<p><strong>Aim: </strong>The study aimed to compare the predictive capabilities of the traditional anthropometric indices with the novel anthropometric indices for incident hypertension.</p><p><strong>Background: </strong>Some novel anthropometric indices, e.g., the Body Roundness Index (BRI) and A Body Shape Index (ABSI) have been associated with prevalent hypertension. There are a few cohort studies that have examined the association of the novel anthropometric indices with newonset hypertension in young adults.</p><p><strong>Methods: </strong>This study included 2,448 military male and female young adults, aged 18-39 years, free of hypertension at baseline in Taiwan; they were followed for incidence of hypertension from 2014 till the end of 2020. Blood Pressure (BP) in mmHg was measured twice and averaged to verify hypertension, which was defined as systolic BP ≥130 and/or diastolic BP ≥80 or on antihypertensive medication therapy in each annual health examination. Anthropometric indices included the Body Mass Index (BMI) defined as the weight (kg)/height squared (m2), Waist Girth (WC) in cm, the Waist-to-height Ratio (WHtR), the BRI defined as 364.2 - 365.5 × {1 - [(WC/2π)/(0.5 × height)]2}0.5, as well as ABSI defined as WC/(BMI2/3 × height1/2). Multiple Cox regression analysis and Area Under the Curve (AUC) of the Receiver of Operating Characteristics (ROC) were utilized with adjustments for the baseline potential covariates to determine the association and compare the performance of various indices for incident hypertension.</p><p><strong>Results: </strong>During a median follow-up period of 6.0 years, 920 new-onset hypertension cases (37.6%) developed. Higher BMI, WC, BRI (per each 1-unit increase) and WHtR (per each 0.1- unit increase) were associated with a greater risk of new-onset hypertension [Hazard Ratios (HRs) and 95% confidence intervals: 1.060 (1.035-1.085), 1.021 (1.011-1.030), and 1.178 (1.077-1.288), respectively], whereas there was no association between ABSI and new-onset hypertension. For the ROC, WC was observed with the greatest AUC for incident new-onset hypertension [0.661 (0.638-0.683)], followed by BMI [0.650 (0.628-0.673)], while the ABSI was found with the lowest AUC [0.544 (0.521-0.568)].</p><p><strong>Conclusion: </strong>Most of the anthropometric indices were associated with a higher risk of new-onset hypertension among young adults, except for ABSI. In addition, this study has suggested the traditional indices, such as WC and BMI, to be superior to the latest ones, e.g., BRI and ABSI, for the prediction of new-onset hypertension.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Post-traumatic Stress on Sexual Function of Survivors of Hematological Malignancies and Autologous Hematopoietic Stem Cell Transplantation.","authors":"Ioanna Tsatsou, Kyriaki Mystakidou, Efi Parpa, Theocharis Konstantinidis, Ioannis Kalemikerakis, Theodoula Adamakidou, Eleni Panagou, Antonis Galanos, Ourania Govina","doi":"10.2174/0118715303294071240710171701","DOIUrl":"https://doi.org/10.2174/0118715303294071240710171701","url":null,"abstract":"<p><strong>Background: </strong>Autolοgous Hematopoietic Stem Cell Transplantation (AHSCT) is a treatment οption fοr patients with hematological malignancies that improves prοgnοsis and survival. Thus, it is necessary tο deal with its long-term cοmplications, such as sexual dysfunction and trauma that significantly affect survivors' quality οf life.</p><p><strong>Objective: </strong>The aim οf this study was to evaluate the Sexual Function (SF) and the Pοst-traumatic Stress Disorder (PTSD) οf survivοrs οf hematolοgical malignancy and AHSCT.</p><p><strong>Methods: </strong>A multicenter, quantitative, crοss-sectional, descriptive, and cοrrelational study was cοnducted from December 2019 to March 2022. Thrοugh cοnvenience sampling, 127 adults and sexually active survivors οf hematolοgic malignancy whο underwent AHSCT frοm 6 mοnths tο 5 years were recruited frοm 5 hοspitals in Athens. The survivοrs cοmpleted questionnaires on demοgraphic and clinical data, a male or female SF assessment tοοl [Internatiοnal Index Erectile Functiοn (IIEF) and Female Sexual Functiοn Index (FSFI), respectively], and the Impact of Event Scale-Revised (IES-R).</p><p><strong>Results: </strong>Patients' mean age was 45.6 (±12.8) years. The median time frοm transplant was 3 years and the majοrity οf the survivοrs had Hodgkin's lymphοma. Accοrding tο the FSFI, wοmen had a mοderate level of SF, with a better functional area the \"pain\" and wοrse the \"οrgasm\". Accοrding tο the IIEF, men had a high level of SF, with a better functional area the \"erection\" and wοrse the \"οverall satisfaction\". Survivοrs had lοw levels οf PTSD based οn the IES-R, with nο differences between men and women. The subscale οf \"hyperarοusal\" had the lοwest values and the subscale οf \"avοidance\" had the highest values fοr bοth men and wοmen survivοrs. There was a lοw tο mοderate negative statistically significant cοrrelation between the IES-R and bοth FSFI and IIEF, suggesting a high level οf PTSD to be correlated with wοrse sexual function.</p><p><strong>Conclusion: </strong>Survivοrs οf AHSCT had impaired SF tο varying degrees and areas of functionality depending οn their gender, but lοw levels of PTSD and lοw correlations between these twο variables. This matter is impοrtant in survivοrship care and needs further investigatiοn.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ectopic Cushing's Syndrome in Pediatric Age","authors":"Guido Roberto, Maria Elena Aloini, Irene Biondo, Francesca Ricci, Roberta Maggio, Pina Lardo, Antonio Stigliano","doi":"10.2174/0118715303333260240715070743","DOIUrl":"10.2174/0118715303333260240715070743","url":null,"abstract":"<p><strong>Background: </strong>Cushing's syndrome due to ectopic ACTH secretion is a rare clinical condition resulting from a dysregulated\u0000ACTH secretion by neuroendocrine tumors. The overall incidence of endogenous Cushing's syndrome is 0.7-2.4 per million people\u0000annually, with children accounting for only 10% of new cases each year.</p><p><strong>Case report: </strong>When the patient first presented clinically, she was a 17-year-old girl who displayed psychiatric symptoms. Blood tests\u0000showed diabetes mellitus and hypokalemia. She had hypertension and vertebral collapses. The hormone assay showed hypercortisolism,\u0000and because of this, she began taking metyrapone. The results of the 68Ga-PET/DOTATOC and 18FDG-PET scans were negative.\u0000The clinical course was intermittent. After one year, a 68Ga-PET/DOTATOC showed a nodule in the thymic lodge. Despite the\u0000thymectomy, the hypercortisolism persisted. A subsequent 68Ga-PET/DOTATOC repeated three months after surgery revealed an\u0000uptake corresponding to the thymic lodge. She underwent another surgery, which is finally being resolved. ACTH levels were monitored\u0000before, during, and post-surgery. The laboratory provided the ACTH results promptly, and thoracic surgeons waited for hormonal\u0000results before concluding the procedure. The adopted strategy permitted us to monitor the surgery outcome.</p><p><strong>Conclusion: </strong>The heterogeneity of ectopic Cushing's syndrome makes diagnosis difficult. 68Ga-PET/DOTATOC proves to be a tracer\u0000with good sensitivity and specificity for the identification of ACTH-secreting neuroendocrine lesions. The short half-life of ACTH is\u0000found to be a strategy to monitor the complete surgical resection of the neuroendocrine lesion.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141750157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TNF-alpha Inhibitors Induced Eosinophilia: A Case Report of an Undervalued Side Effect of Such Biologicals","authors":"Federico Diomeda, Gianfranco Calogiuri, Maurizio Congedo, Angela Filoni, Emiliano Sordi, Massimo Fiore, Lucia Pietroleonardo, Prisco Piscitelli, Adele Civino","doi":"10.2174/0118715303309437240703114340","DOIUrl":"10.2174/0118715303309437240703114340","url":null,"abstract":"<p><strong>Introduction: </strong>We present an unusual case of a 28-year-old rheumatologic male patient who developed eosinophilia while he was on etanercept therapy first and then on golimumab.</p><p><strong>Case representation: </strong>Although eosinophilia is rarely reported in the literature as a side-effect of various Tumor Necrosis Factor-alpha [TNF-alpha] antagonists, it represents a riddle about the future treatments of these patients since the persistence of therapy might lead to the onset of dermatologic or visceral eosinophilic complications in such patients.</p><p><strong>Conclusion: </strong>Furthermore, the pathogenesis of eosinophilia is still unknown, and all the proposed hypotheses do not explain the eosinophilic proliferation in certain subjects.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141750160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender Incongruence: Prevalence and Therapeutic Options Among Transsexuals Belonging to a Single Center.","authors":"Mario Giuseppe Vetri, Annamia Greco, Cinzia Tobino, Giovanni Rapisardi, Giuseppe Grasso, Anna Maria D'Agata","doi":"10.2174/0118715303333948240715070651","DOIUrl":"https://doi.org/10.2174/0118715303333948240715070651","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to describe characteristics and treatment choices among AMABs (Assigned Male At Birth) and AFABs (Assigned Female At Birth) transgenders enrolled from March 2021 to July 2023 at the PTA S. Giorgio of the ASP3-Catania.</p><p><strong>Case history: </strong>A total of 145 patients were studied, and there was no prevalence of AMAB/AFAB. At first observation for AMABs, the age was 26 years and 25 years for AFABs, with 11 AMAB/AFAB declared as \"non-binary\" (average age 17 years).</p><p><strong>Results: </strong>In AMAB/AFAB, we evaluated hormonal treatment, efficacy, and dosage/hormonal levels. In AMABs, oral estradiol valerate (4 mg/day) or transdermal estradiol in gel (2 mg/day) + oral cyproterone acetate (25 mg/day) for both estrogenic formulations were used. Testosterone (TE), LH, FSH, and PRL at baseline and during chronic treatment were measured. In AFABs, we used injectable TE (250 mg/3-4 weeks or 1 g/12-16 weeks) or transdermal TE (60- 80 mg/day). In these patients, we analyzed blood count, LH, FSH, and TE. Hematocrit, hemoglobin, and red blood cell count showed a modest elevation after 4-6 months of treatment. About 32% of AFABs complained of transient uterine bleeding, but no hypertension or ovarian pathology was detected.</p><p><strong>Conclusion: </strong>In AMABs, despite the short observation period, no patient showed an increased risk of myocardial infarction and ischemic stroke. Among AFABs, no increased risk of cardiovascular or cerebrovascular disease was observed. Furthermore, given the complexity of the phenomenon, the integration between the different professional figures who require specific and qualified skills is fundamental.</p>.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141750159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Semaglutide in Reactive Hypoglycemia Related to Dumping Syndrome after Bariatric Surgery.","authors":"Angelo Fiore, Santoro Gaetano, Lombardo Ausilia, Spitali Federica, Sceusa Giulia, Gullo Damiano","doi":"10.2174/0118715303318399240715065513","DOIUrl":"https://doi.org/10.2174/0118715303318399240715065513","url":null,"abstract":"<p><strong>Introduction: </strong>Postprandial hypoglycemia induced by Dumping Syndrome (DS) represents a side effect of bariatric surgery linked to glucose-dependent hyperinsulinemia, which can cause serious symptoms 2-3 hours after the meal hypoglycemia. This clinical case shows the effectiveness of semaglutide, a long-acting GLP1 receptor agonist, in one patient previously subjected to gastric bypass (GBP), with persistent late postprandial hypoglycaemic symptoms occurring after surgery.</p><p><strong>Case report: </strong>A female patient, 31 years old, subjected to GBP 10 years earlier, with the diagnosis of diabetes, was admitted to our unit for persistent post-prandial reactive hypoglycemia, confirmed by Flash Glucose Monitoring (FGM) FreeStyle. The patient was intolerant to metformin, had been treated with acarbose with poor results. HbA1c 7.9%. Acarbose was suspended, and semaglutide was started sc at increasing doses, 0.25 mg/week for 1 month and subsequently 0.5 mg/week. After the first few weeks, symptoms of DS were significantly reduced with improvement of the daily glycemic profile and disappearance of hypoglycemic events. The time-below range, time spent with blood glucose <70 mg/dl, decreased by 12% to 4% during treatment with semaglutide 0.25 mg/week, up to 1% with a dose of 0.5 mg/week. The effect of the drug on reducing hypoglycemic episodes was persistent for up to 8 months.</p><p><strong>Conclusion: </strong>Treatment of post-bariatric reactive hypoglycemia includes nutritional therapy, the use of glucosidase inhibitors, and somatostatin analogues. The use of short-acting GLP-1RA analogues has also recently been reported. In our patient, therapy with semaglutide s.c. significantly reduced episodes of reactive hypoglycemia with an improvement in the quality of life.</p>.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141750158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}